TFF, Augmenta Bioworks partner on COVID-19 mAbs

By The Science Advisory Board staff writers

November 2, 2020 -- TFF Pharmaceuticals and Augmenta Bioworks have agreed to work together to develop COVID-19 monoclonal antibody (mAb) therapies.

The companies will apply TFF Pharmaceuticals' thin-film freezing (TFF) technology to Augmenta's human-derived mAbs as a potential treatment for COVID-19. The technology will be used to manufacture dry powder formulations of these specific mAbs for inhalation delivery directly to the lungs of patients, according to their agreement.

The companies also agreed to develop formulations suitable for parenteral administration. The TFF dry powder formulas would be reconstituted, potentially mitigating the impacts of cold-chain storage and handling.

Nanoform begins first-in-human trial by year end
Nanoform Finland plans to start the first human clinical trial of its drug candidate using the company's Controlled Expansion of Supercritical Solutions...
Union Therapeutics licenses COVID-19 tech from TFF
Union Therapeutics has completed an agreement with TFF Pharmaceuticals to obtain a worldwide exclusive license for the use of its thin film freezing technology...
Universal flu vaccine R&D collaboration established
Clinical-stage biopharmaceutical company TFF Pharmaceuticals has partnered with researchers at the University of Georgia and University of Texas to evaluate...

Copyright © 2020

Laboratory Products Association Annual Meeting
October 1-4
Scottsdale, Arizona United States
Cell & Gene Meeting on the Mesa
October 11-13
Carlsbad, California United States
IDWeek 2022
October 19-23
District of Columbia United States
American Society of Human Genetics Annual Meeting
October 25-29
Los Angeles, California United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter